RxDoctor Payments Data

John Molina

Hematology · Cleveland, OHNPI 1043622855

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $33,316 of the $38,811 with a category attached, or 85.8%. Jazz Pharmaceuticals Inc. accounts for 89.3% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $34,905, more than ten times the $23 reported in 2023.

$38,811in general payments, 2019–2025

Across 43 payments — averaging $902.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$35K
  • Autolus Inc$3K
  • AstraZeneca$400
  • Sobi, Inc$228
  • Rigel Pharmaceuticals, Inc.$148
  • Regeneron Healthcare Solutions, Inc.$144
  • plus $134 from 3 others

What the payments were for

  • Consulting fees$6002%
  • Speaking & faculty fees$33,31686%
  • Travel & lodging$3,6859%
  • Food & beverage$1,2113%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$38,811 in reported general payments places this provider in the 80th percentile of 84 hematology providers in Ohio.

See all hematology providers in Ohio

Medicare billing

Part B allowed, 2024
$27,369
Medicare patients
69
Services billed
253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OjjaaraMomelotinib Dihydrochloride21$580,948
JakafiRuxolitinib Phosphate16$271,919
IclusigPonatinib Hcl13$241,987
Acyclovir26$311
Levofloxacin18$149
Gabapentin15$146
Hydroxyurea15$110
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim15$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$72$271,91916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 84 hematology providers in Ohio.

Other hematology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →